Background : The role of acute phase reactants including the hs CRP and serum fibrinogen in predicting future cardiovascular risk is well known. But the impact of pre-procedural serum fibrinogen which is also an essential clotting factor, on the in-hospital outcomes after the percutenous coronary interventions (PCI) with drug-eluting stent (DES) is largely unknown. Methods : This study consisted of 637 consecutive patients (pts) underwent PCI with DES between 2007 and 2008. Pts were divided into normal or low fibrinogen level (<400 mg/dl) group (N=518 pts, 81.3%) and high fibrinogen level (>400 mg/dl) group (N=119 pts, 18.7%). We investigated whether there is increased risk of in-hospital bleeding and vascular complications and major clinical outcomes in pts with high fibrinogen level. Results : The baseline characteristics were similar between the two groups except the low density lipoprotein cholesterol level was higher in the pts with high fibrinogen level. In univariate analysis, the incidence of major bleeding was higher in pts with high fibrinogen level group. However, after the multivariate analysis, there was no significant difference in the any bleeding or vascular complications. In-hospital major clinical events including deaths, myocardial infarction and repeat revascularization were similar between the two groups (Table).Conclusions : Pts with high level of fibrinogen at baseline before PCI did not impact on major bleeding and vascular complications or major in-hospital cardiovascular events compared with those of pts with normal or low fibrinogen level. Further prospective studies with larger number of pts are warranted to assess the significance of abnormal fibrinogen levels.